Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02988440 |
Title | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Novartis Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | ESP | DEU | CAN |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Karmanos Cancer Institute | Detroit | Michigan | 48201 | United States | Details | |
Novartis Investigative Site | Montreal | Quebec | H3T 1E2 | Canada | Details | |
Novartis Investigative Site | Essen | 45147 | Germany | Details | ||
Novartis Investigative Site | Hong Kong | Hong Kong | Details | |||
Novartis Investigative Site | Rozzano | MI | 20089 | Italy | Details | |
Novartis Investigative Site | Kashiwa | Chiba | 277 8577 | Japan | Details | |
Novartis Investigative Site | Yokohama city | Kanagawa | 232 0024 | Japan | Details | |
Novartis Investigative Site | Pamplona | Navarra | 31008 | Spain | Details | |
Novartis Investigative Site | Taipei | 10002 | Taiwan | Details |